Martin Johnson
AstraZeneca
9 Papers
5 Citations
Martin Johnson is an academic researcher from AstraZeneca. The author has contributed to research in topics: Osimertinib & Population. The author has an hindex of 5, co-authored 9 publications. Previous affiliations of Martin Johnson include University of Groningen.
Chat about Author
Papers
Osimertinib for Patients With Leptomeningeal Metastases Associated With EGFR T790M-Positive Advanced NSCLC: The AURA Leptomeningeal Metastases Analysis
Myung-Ju Ahn,Chao-Hua Chiu,Ying Cheng,Ji-Youn Han,Sarah B. Goldberg,Alastair Greystoke,Jeffrey Crawford,Yanqiu Zhao,X. Huang,Martin Johnson,Karthick Vishwanathan,James W.T. Yates,Andrew P. Brown,Ariadna Mendoza-Naranjo,Tony Mok +14 more
TL;DR: Patients with EGFR T790M-positive NSCLC and radiologically detected LM obtained clinical benefit from osimertinib (80 mg qd) and similar non-CNS and LM responses between the patients in AURA LM and BLOOM programs were revealed.
135
Machine Learning Models for Human In Vivo Pharmacokinetic Parameters with In-House Validation.
Filip Miljković,Anton Martinsson,Olga Obrezanova,Beth Williamson,Martin Johnson,Andy Sykes,Andreas Bender,Andreas Bender,Nigel Greene +8 more
TL;DR: In this article, a comprehensive data curation protocol was established to enable machine learning evaluation of 12 human in vivo pharmacokinetic parameters using only chemical structure information and available doses for 1001 unique compounds.
56
Pharmacokinetic Study of Osimertinib in Cancer Patients with Mild or Moderate Hepatic Impairment
Enrique Grande,R. Donald Harvey,Benoit You,Jaime Feliu Batlle,Hal Galbraith,John Sarantopoulos,Suresh S. Ramalingam,Helen Mann,Karen So,Martin Johnson,Karthick Vishwanathan +10 more
TL;DR: Comparison of these study results with National Cancer Institute-Organ Dysfunction Working Group criteria from population PK analysis showed osimertinib exposure was not affected by hepatic impairment.
17
Translational Modeling in Schizophrenia: Predicting Human Dopamine D2 Receptor Occupancy
Martin Johnson,Martin Johnson,Magdalena Kozielska,Magdalena Kozielska,Venkatesh Pilla Reddy,Venkatesh Pilla Reddy,An Vermeulen,Hugh A. Barton,Sarah Grimwood,Rik de Greef,Geny M. M. Groothuis,Meindert Danhof,Johannes H. Proost +12 more
TL;DR: The rat hybrid PBPKPD model structure, integrated with in vitro information and human pharmacokinetic and physiological information, constitutes a scientific basis to predict the time course of D2RO in man.
Gefitinib exposure and occurrence of interstitial lung disease in Japanese patients with non-small-cell lung cancer
Toshio Kawata,Mitsuo Higashimori,Yohji Itoh,Helen Tomkinson,Martin Johnson,Weifeng Tang,Fredrik Nyberg,Haiyi Jiang,Yusuke Tanigawara +8 more
TL;DR: Significant elevation of exposure of gefitinib was observed at the time of ILD occurrence, suggesting reduction of CL/F could be associated with ILD-induced AGP elevation.